AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement
BackgroundHip involvement is a severe prognostic factor and may lead to a worse functional outcome.ObjectivesTo assess clinical and radiological progression in patient with hip involvement and to assess the impact of TNF inhibitors treatment in this population with severe prognostic factor.MethodsAx...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.1148 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl 2 |
container_start_page | 1148 |
container_title | Annals of the rheumatic diseases |
container_volume | 74 |
creator | Mahmoud, I. Maatallah, K. Belghani, S. Saidane, O. Ben Abdelghani, K. Metoui, L. Hamdi, W. Tekaya, R. Abdelmoula, L. |
description | BackgroundHip involvement is a severe prognostic factor and may lead to a worse functional outcome.ObjectivesTo assess clinical and radiological progression in patient with hip involvement and to assess the impact of TNF inhibitors treatment in this population with severe prognostic factor.MethodsAxial Spondyloarthritis (AS) patients (satisfying ASAS criteria 2009) with hip involvement with at least two sets of Antero-posterior X-rays of the pelvis at a minimum gap of 2 years were included. Demographic, clinical, radiographic, and laboratory data were collected and analyzed. Radiographic severity was assessed by the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and BASRI (Bath Ankylosing Spondylitis Radiologic Index).Results84 patients were evaluated, the median age of onset of the disease was 25 years [16-54ans], HLA B27 was positive in 50% of cases. Forty six patients received TNF inhibitors (infliximab 48%, Adalimumab 14% and Etanercept 36%), 27 patients received csDMARDs and 46 NSAID. Sixty four patients had bilateral hip involvement. At baseline: the median BASDAI and BASFI scores were respectively 5,4 and 5,5. The average ESR and CRP were respectively 47 and 33. The average BASRI spine was 3, the median BASRI hip was 2 and the median mSASSS was 15. At 2years: The median BASDAI and BASFI scores were respectively 3,4 and 3,6. The average ESR and CRP were respectively 34 and 15. the average BASRI spine was 3,7, the median BASRI hip was 2 the median mSASSS was 19. After an average of 5years: The median BASDAI and BASFI scores were respectively 2,9 and 3,8. The average ESR and CRP were respectively 32 and 20. When we compared TNF inhibitors patients versus TNF naïf, there were no significant difference in age of onset, HLA B27, ESR, CRP, BASRI and mSASSS at baseline between the two groups, however TNF inhibitors patients had a higher BASDAI and BASFI scores. At 2 years: TNF inhibitors patients had a significantly lesser BASDAI and BASFI scores. At an average of 5years: TNF inhibitors patients had significantly lesser BASDAI, BASFI and BASRI hip scores. TNF inhibitors have a protective effect on radiographic hip progression OR 5.07 [IC1.86-13.8]ConclusionsContrary to what has been reported in several studies on the effectiveness of TNF inhibitors on radiological spine progression, this has not been proved in our study, however TNF inhibitors patients showed a less trend for radiological hip progression.Disclosure of InterestNone declared |
doi_str_mv | 10.1136/annrheumdis-2015-eular.6443 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901780720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322503079</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-dc13a9bc60543fc19e215c32a817a838f3fd7ad83bdd3eb275779d06119496363</originalsourceid><addsrcrecordid>eNqVkMFOwzAQRC0EEqXwD5Z6DthxYjviVCqglSpRQTlbTuy0Lokd7KSoNy78KF9C2nLgymk1o5ld7QNghNE1xoTeSGv9Wne1MiGKEU4j3VXSX9MkISdggBPKe5uiUzBACJEoySg7BxchbHqJOOYD8Da-QyxJvz-_JpWxppAVlFbBZ6mMq9zqYCy8W3kdgnEWGgtfGmfVrnLSt2tvWqMDXHbWBCMtXMhe2zbAD9Ou4dQ0cGa3rtrquncvwVkpq6CvfucQvD7cLyfTaP70OJuM51GOY4YiVWAis7ygKE1IWeBMxzgtSCw5ZpITXpJSMak4yZUiOo9ZylimEMU46x8klAzB6Li38e6906EVG9d5258UOEOYccRi1Kduj6nCuxC8LkXjTS39TmAk9nTFH7piT1cc6Io93b5Nj-283vyr-ANmAYe0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901780720</pqid></control><display><type>article</type><title>AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement</title><source>BMJ Journals - NESLi2</source><creator>Mahmoud, I. ; Maatallah, K. ; Belghani, S. ; Saidane, O. ; Ben Abdelghani, K. ; Metoui, L. ; Hamdi, W. ; Tekaya, R. ; Abdelmoula, L.</creator><creatorcontrib>Mahmoud, I. ; Maatallah, K. ; Belghani, S. ; Saidane, O. ; Ben Abdelghani, K. ; Metoui, L. ; Hamdi, W. ; Tekaya, R. ; Abdelmoula, L.</creatorcontrib><description>BackgroundHip involvement is a severe prognostic factor and may lead to a worse functional outcome.ObjectivesTo assess clinical and radiological progression in patient with hip involvement and to assess the impact of TNF inhibitors treatment in this population with severe prognostic factor.MethodsAxial Spondyloarthritis (AS) patients (satisfying ASAS criteria 2009) with hip involvement with at least two sets of Antero-posterior X-rays of the pelvis at a minimum gap of 2 years were included. Demographic, clinical, radiographic, and laboratory data were collected and analyzed. Radiographic severity was assessed by the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and BASRI (Bath Ankylosing Spondylitis Radiologic Index).Results84 patients were evaluated, the median age of onset of the disease was 25 years [16-54ans], HLA B27 was positive in 50% of cases. Forty six patients received TNF inhibitors (infliximab 48%, Adalimumab 14% and Etanercept 36%), 27 patients received csDMARDs and 46 NSAID. Sixty four patients had bilateral hip involvement. At baseline: the median BASDAI and BASFI scores were respectively 5,4 and 5,5. The average ESR and CRP were respectively 47 and 33. The average BASRI spine was 3, the median BASRI hip was 2 and the median mSASSS was 15. At 2years: The median BASDAI and BASFI scores were respectively 3,4 and 3,6. The average ESR and CRP were respectively 34 and 15. the average BASRI spine was 3,7, the median BASRI hip was 2 the median mSASSS was 19. After an average of 5years: The median BASDAI and BASFI scores were respectively 2,9 and 3,8. The average ESR and CRP were respectively 32 and 20. When we compared TNF inhibitors patients versus TNF naïf, there were no significant difference in age of onset, HLA B27, ESR, CRP, BASRI and mSASSS at baseline between the two groups, however TNF inhibitors patients had a higher BASDAI and BASFI scores. At 2 years: TNF inhibitors patients had a significantly lesser BASDAI and BASFI scores. At an average of 5years: TNF inhibitors patients had significantly lesser BASDAI, BASFI and BASRI hip scores. TNF inhibitors have a protective effect on radiographic hip progression OR 5.07 [IC1.86-13.8]ConclusionsContrary to what has been reported in several studies on the effectiveness of TNF inhibitors on radiological spine progression, this has not been proved in our study, however TNF inhibitors patients showed a less trend for radiological hip progression.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.6443</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1148</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1148.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1148.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Mahmoud, I.</creatorcontrib><creatorcontrib>Maatallah, K.</creatorcontrib><creatorcontrib>Belghani, S.</creatorcontrib><creatorcontrib>Saidane, O.</creatorcontrib><creatorcontrib>Ben Abdelghani, K.</creatorcontrib><creatorcontrib>Metoui, L.</creatorcontrib><creatorcontrib>Hamdi, W.</creatorcontrib><creatorcontrib>Tekaya, R.</creatorcontrib><creatorcontrib>Abdelmoula, L.</creatorcontrib><title>AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement</title><title>Annals of the rheumatic diseases</title><description>BackgroundHip involvement is a severe prognostic factor and may lead to a worse functional outcome.ObjectivesTo assess clinical and radiological progression in patient with hip involvement and to assess the impact of TNF inhibitors treatment in this population with severe prognostic factor.MethodsAxial Spondyloarthritis (AS) patients (satisfying ASAS criteria 2009) with hip involvement with at least two sets of Antero-posterior X-rays of the pelvis at a minimum gap of 2 years were included. Demographic, clinical, radiographic, and laboratory data were collected and analyzed. Radiographic severity was assessed by the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and BASRI (Bath Ankylosing Spondylitis Radiologic Index).Results84 patients were evaluated, the median age of onset of the disease was 25 years [16-54ans], HLA B27 was positive in 50% of cases. Forty six patients received TNF inhibitors (infliximab 48%, Adalimumab 14% and Etanercept 36%), 27 patients received csDMARDs and 46 NSAID. Sixty four patients had bilateral hip involvement. At baseline: the median BASDAI and BASFI scores were respectively 5,4 and 5,5. The average ESR and CRP were respectively 47 and 33. The average BASRI spine was 3, the median BASRI hip was 2 and the median mSASSS was 15. At 2years: The median BASDAI and BASFI scores were respectively 3,4 and 3,6. The average ESR and CRP were respectively 34 and 15. the average BASRI spine was 3,7, the median BASRI hip was 2 the median mSASSS was 19. After an average of 5years: The median BASDAI and BASFI scores were respectively 2,9 and 3,8. The average ESR and CRP were respectively 32 and 20. When we compared TNF inhibitors patients versus TNF naïf, there were no significant difference in age of onset, HLA B27, ESR, CRP, BASRI and mSASSS at baseline between the two groups, however TNF inhibitors patients had a higher BASDAI and BASFI scores. At 2 years: TNF inhibitors patients had a significantly lesser BASDAI and BASFI scores. At an average of 5years: TNF inhibitors patients had significantly lesser BASDAI, BASFI and BASRI hip scores. TNF inhibitors have a protective effect on radiographic hip progression OR 5.07 [IC1.86-13.8]ConclusionsContrary to what has been reported in several studies on the effectiveness of TNF inhibitors on radiological spine progression, this has not been proved in our study, however TNF inhibitors patients showed a less trend for radiological hip progression.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkMFOwzAQRC0EEqXwD5Z6DthxYjviVCqglSpRQTlbTuy0Lokd7KSoNy78KF9C2nLgymk1o5ld7QNghNE1xoTeSGv9Wne1MiGKEU4j3VXSX9MkISdggBPKe5uiUzBACJEoySg7BxchbHqJOOYD8Da-QyxJvz-_JpWxppAVlFbBZ6mMq9zqYCy8W3kdgnEWGgtfGmfVrnLSt2tvWqMDXHbWBCMtXMhe2zbAD9Ou4dQ0cGa3rtrquncvwVkpq6CvfucQvD7cLyfTaP70OJuM51GOY4YiVWAis7ygKE1IWeBMxzgtSCw5ZpITXpJSMak4yZUiOo9ZylimEMU46x8klAzB6Li38e6906EVG9d5258UOEOYccRi1Kduj6nCuxC8LkXjTS39TmAk9nTFH7piT1cc6Io93b5Nj-283vyr-ANmAYe0</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Mahmoud, I.</creator><creator>Maatallah, K.</creator><creator>Belghani, S.</creator><creator>Saidane, O.</creator><creator>Ben Abdelghani, K.</creator><creator>Metoui, L.</creator><creator>Hamdi, W.</creator><creator>Tekaya, R.</creator><creator>Abdelmoula, L.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement</title><author>Mahmoud, I. ; Maatallah, K. ; Belghani, S. ; Saidane, O. ; Ben Abdelghani, K. ; Metoui, L. ; Hamdi, W. ; Tekaya, R. ; Abdelmoula, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-dc13a9bc60543fc19e215c32a817a838f3fd7ad83bdd3eb275779d06119496363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahmoud, I.</creatorcontrib><creatorcontrib>Maatallah, K.</creatorcontrib><creatorcontrib>Belghani, S.</creatorcontrib><creatorcontrib>Saidane, O.</creatorcontrib><creatorcontrib>Ben Abdelghani, K.</creatorcontrib><creatorcontrib>Metoui, L.</creatorcontrib><creatorcontrib>Hamdi, W.</creatorcontrib><creatorcontrib>Tekaya, R.</creatorcontrib><creatorcontrib>Abdelmoula, L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahmoud, I.</au><au>Maatallah, K.</au><au>Belghani, S.</au><au>Saidane, O.</au><au>Ben Abdelghani, K.</au><au>Metoui, L.</au><au>Hamdi, W.</au><au>Tekaya, R.</au><au>Abdelmoula, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>1148</spage><pages>1148-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundHip involvement is a severe prognostic factor and may lead to a worse functional outcome.ObjectivesTo assess clinical and radiological progression in patient with hip involvement and to assess the impact of TNF inhibitors treatment in this population with severe prognostic factor.MethodsAxial Spondyloarthritis (AS) patients (satisfying ASAS criteria 2009) with hip involvement with at least two sets of Antero-posterior X-rays of the pelvis at a minimum gap of 2 years were included. Demographic, clinical, radiographic, and laboratory data were collected and analyzed. Radiographic severity was assessed by the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and BASRI (Bath Ankylosing Spondylitis Radiologic Index).Results84 patients were evaluated, the median age of onset of the disease was 25 years [16-54ans], HLA B27 was positive in 50% of cases. Forty six patients received TNF inhibitors (infliximab 48%, Adalimumab 14% and Etanercept 36%), 27 patients received csDMARDs and 46 NSAID. Sixty four patients had bilateral hip involvement. At baseline: the median BASDAI and BASFI scores were respectively 5,4 and 5,5. The average ESR and CRP were respectively 47 and 33. The average BASRI spine was 3, the median BASRI hip was 2 and the median mSASSS was 15. At 2years: The median BASDAI and BASFI scores were respectively 3,4 and 3,6. The average ESR and CRP were respectively 34 and 15. the average BASRI spine was 3,7, the median BASRI hip was 2 the median mSASSS was 19. After an average of 5years: The median BASDAI and BASFI scores were respectively 2,9 and 3,8. The average ESR and CRP were respectively 32 and 20. When we compared TNF inhibitors patients versus TNF naïf, there were no significant difference in age of onset, HLA B27, ESR, CRP, BASRI and mSASSS at baseline between the two groups, however TNF inhibitors patients had a higher BASDAI and BASFI scores. At 2 years: TNF inhibitors patients had a significantly lesser BASDAI and BASFI scores. At an average of 5years: TNF inhibitors patients had significantly lesser BASDAI, BASFI and BASRI hip scores. TNF inhibitors have a protective effect on radiographic hip progression OR 5.07 [IC1.86-13.8]ConclusionsContrary to what has been reported in several studies on the effectiveness of TNF inhibitors on radiological spine progression, this has not been proved in our study, however TNF inhibitors patients showed a less trend for radiological hip progression.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.6443</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1148 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1901780720 |
source | BMJ Journals - NESLi2 |
title | AB0745 Clinical and Radiological Progression in Spondyloarthrities Tunisian Patients with Hip Involvement |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A59%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0745%E2%80%85Clinical%20and%20Radiological%20Progression%20in%20Spondyloarthrities%20Tunisian%20Patients%20with%20Hip%20Involvement&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Mahmoud,%20I.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=1148&rft.pages=1148-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.6443&rft_dat=%3Cproquest_cross%3E4322503079%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901780720&rft_id=info:pmid/&rfr_iscdi=true |